Stryker (NYSE:SYK) Stock Rating Upgraded by StockNews.com

Stryker (NYSE:SYK) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday.

SYK has been the topic of a number of other research reports. Stifel Nicolaus boosted their price objective on shares of Stryker from $350.00 to $375.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Citigroup increased their price target on shares of Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. BTIG Research increased their price target on shares of Stryker from $366.00 to $369.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Piper Sandler upped their price objective on shares of Stryker from $375.00 to $380.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Finally, The Goldman Sachs Group initiated coverage on Stryker in a research report on Thursday, May 30th. They issued a “neutral” rating and a $372.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $370.58.

Stryker Stock Up 0.4 %

NYSE:SYK opened at $340.79 on Tuesday. The firm has a market cap of $129.82 billion, a P/E ratio of 38.82, a P/E/G ratio of 2.67 and a beta of 0.92. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.99 and a current ratio of 1.71. Stryker has a fifty-two week low of $249.98 and a fifty-two week high of $361.41. The firm has a 50-day simple moving average of $336.73 and a two-hundred day simple moving average of $332.95.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.36 by $0.14. The company had revenue of $5.24 billion for the quarter, compared to the consensus estimate of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The firm’s revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the firm posted $2.14 earnings per share. Analysts predict that Stryker will post 11.95 earnings per share for the current fiscal year.

Institutional Trading of Stryker

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Burkett Financial Services LLC acquired a new position in Stryker in the 4th quarter valued at about $25,000. Farmers & Merchants Trust Co of Chambersburg PA boosted its stake in shares of Stryker by 203.3% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after buying an additional 61 shares during the period. Rogco LP purchased a new position in shares of Stryker in the 4th quarter valued at about $30,000. DSM Capital Partners LLC purchased a new position in shares of Stryker in the 4th quarter valued at about $34,000. Finally, HBC Financial Services PLLC purchased a new position in shares of Stryker in the 4th quarter valued at about $37,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.